LifeStance Health Group (NASDAQ:LFST) to Repurchase $100.00 million in Outstanding Stock

LifeStance Health Group (NASDAQ:LFST) declared that its board has authorized a stock buyback program on Wednesday, February 25th, RTT News reports. The company plans to buyback $100.00 million in outstanding shares. This buyback authorization authorizes the company to reacquire up to 3.6% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s leadership believes its shares are undervalued.

Analyst Upgrades and Downgrades

Several analysts have issued reports on LFST shares. Barclays began coverage on shares of LifeStance Health Group in a research report on Tuesday, December 9th. They set an “overweight” rating and a $8.00 price target on the stock. Zacks Research cut shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 5th. UBS Group lifted their price target on LifeStance Health Group from $9.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, November 7th. Wall Street Zen raised LifeStance Health Group from a “hold” rating to a “buy” rating in a research report on Sunday, February 8th. Finally, BMO Capital Markets started coverage on LifeStance Health Group in a research note on Thursday, November 13th. They issued an “outperform” rating and a $8.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $9.00.

LifeStance Health Group Trading Up 3.8%

Shares of LFST stock opened at $7.41 on Thursday. LifeStance Health Group has a 12-month low of $3.74 and a 12-month high of $8.30. The company has a market capitalization of $2.88 billion, a PE ratio of -247.00 and a beta of 1.12. The firm has a 50 day moving average price of $7.12 and a two-hundred day moving average price of $6.18. The company has a quick ratio of 1.58, a current ratio of 1.58 and a debt-to-equity ratio of 0.18.

LifeStance Health Group News Summary

Here are the key news stories impacting LifeStance Health Group this week:

• Positive Sentiment: Q4 operational and financial beat — Revenue grew 17% to $382.2M, visit volumes +18% and clinician base +9%; Q4 net income of $11.7M and Adjusted EBITDA of $48.8M showed margin improvement and stronger cash flow, supporting the positive reaction. LifeStance Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: 2026 outlook and capital return — Company guided FY2026 revenue $1.615B–$1.655B and Adjusted EBITDA $185M–$205M, and the Board authorized a $100M share repurchase program, both of which support longer‑term valuation. LifeStance Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Analyst/market reaction — Revenue beat consensus and several outlets noted the upside, driving a sharp intraday rally as investors priced improved operating leverage and growth momentum. LifeStance Health Group (NASDAQ:LFST) Posts Better-Than-Expected Sales In Q4 CY2025, Stock Jumps 12.7%
• Neutral Sentiment: Earnings call / transcript — Management hosted the Q4 call and provided details on clinician productivity, margin drivers and guidance assumptions; review the transcript/slides for color on cadence and execution risk. LifeStance (LFST) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Secondary offering by existing holders — Certain selling stockholders filed to offer 25,000,000 existing shares; LifeStance is not selling shares and receives no proceeds. The large proposed resale increases potential supply and could pressure the stock despite operational strength. LifeStance Health Group Announces Launch of Secondary Public Offering
• Negative Sentiment: Mixed EPS reads and volatility risk — Depending on the metric, outlets reported slightly different EPS comparisons (some show a beat on adjusted metrics while others cite a miss vs. a near-term consensus), which can drive short-term volatility; trading volume has been elevated. LifeStance Health Group Inc Earnings Report (MarketBeat)

Insider Activity at LifeStance Health Group

In other news, Director Robert Bessler sold 119,942 shares of the business’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $7.04, for a total value of $844,391.68. Following the completion of the sale, the director owned 1,318,983 shares of the company’s stock, valued at approximately $9,285,640.32. The trade was a 8.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Ann Varanakis sold 50,000 shares of the company’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $6.90, for a total transaction of $345,000.00. Following the completion of the transaction, the insider owned 315,610 shares in the company, valued at $2,177,709. This trade represents a 13.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 270,086 shares of company stock valued at $1,891,264. 3.20% of the stock is currently owned by insiders.

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.